Jorge Vela‐Ojeda

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

Neil P. Shah, Hagop M. Kantarjian, Dong‐Wook Kim et al. · Journal of Clinical Oncology · 2008 · 488 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Neha Shah, D.-W. Kim, Hagop M. Kantarjian et al. · Haematologica · 2010 · 243 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant

Parameswaran Hari, M-J Zhang, Vivek Roy et al. · Leukemia · 2009 · 101 citations · Full text

Medicine, Oncology, Surgery +14

Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research

Anuj Mahindra, M Kalaycio, Jorge Vela‐Ojeda et al. · Leukemia · 2011 · 100 citations · Full text

Medicine, Hematology, Oncology +13

Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study

Vânia Hungria, Carlos Chiattone, Miguel Arturo Pavlovsky et al. · Journal of Global Oncology · 2019 · 78 citations · Full text

Medicine, Hematology, Oncology +15